463 related articles for article (PubMed ID: 33992189)
41. Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
Müller T; Schlegel E; Zingler S; Thiede HM
Cells; 2022 Apr; 11(9):. PubMed ID: 35563817
[TBL] [Abstract][Full Text] [Related]
42. Methylenetetrahydrofolate reductase genotype, vitamin B12, and folate influence plasma homocysteine in hemodialysis patients.
Nakamura T; Saionji K; Hiejima Y; Hirayama H; Tago K; Takano H; Tajiri M; Hayashi K; Kawabata M; Funamizu M; Makita Y; Hata A
Am J Kidney Dis; 2002 May; 39(5):1032-9. PubMed ID: 11979347
[TBL] [Abstract][Full Text] [Related]
43. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
Castro A; Valldeoriola F; Linazasoro G; Rodriguez-Oroz MC; Stochi F; Marin C; Rodriguez M; Vaamonde J; Jenner P; Alvarez L; Pavon N; Macias R; Luquin MR; Hernandez B; Grandas F; Gimenez-Roldan S; Tolosa E; Obeso JA
Neurologia; 2005 May; 20(4):180-8. PubMed ID: 15891947
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
Poewe WH; Deuschl G; Gordin A; Kultalahti ER; Leinonen M;
Acta Neurol Scand; 2002 Apr; 105(4):245-55. PubMed ID: 11939936
[TBL] [Abstract][Full Text] [Related]
45. Hyperhomocysteinemia in patients with Parkinson's disease and relationship to vitamin B level.
Shin HW; Sohn YH
J Mov Disord; 2009 May; 2(1):33-6. PubMed ID: 24868350
[TBL] [Abstract][Full Text] [Related]
46. Endothelial dysfunction and hyperhomocysteinemia in Parkinson's disease: flow-mediated dilation study.
Yoon JH; Lee JS; Yong SW; Hong JM; Lee PH
Mov Disord; 2014 Oct; 29(12):1551-5. PubMed ID: 25154960
[TBL] [Abstract][Full Text] [Related]
47. Features of Plasma Homocysteine, Vitamin B12, and Folate in Parkinson's Disease: An Updated Meta-Analysis.
Liu Y; Gou M; Guo X
J Integr Neurosci; 2023 Aug; 22(5):115. PubMed ID: 37735121
[TBL] [Abstract][Full Text] [Related]
48. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Fung VS; Herawati L; Wan Y; ;
Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
[TBL] [Abstract][Full Text] [Related]
49. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease.
Białecka M; Kurzawski M; Roszmann A; Robowski P; Sitek EJ; Honczarenko K; Gorzkowska A; Budrewicz S; Mak M; Jarosz M; Gołąb-Janowska M; Koziorowska-Gawron E; Droździk M; Sławek J
Pharmacogenet Genomics; 2012 Oct; 22(10):716-24. PubMed ID: 22890010
[TBL] [Abstract][Full Text] [Related]
50. The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia.
Guo G; Xu S; Cao LD; Wu QY
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2409-12. PubMed ID: 27338068
[TBL] [Abstract][Full Text] [Related]
51. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
Corvol JC; Bonnet C; Charbonnier-Beaupel F; Bonnet AM; Fiévet MH; Bellanger A; Roze E; Meliksetyan G; Ben Djebara M; Hartmann A; Lacomblez L; Vrignaud C; Zahr N; Agid Y; Costentin J; Hulot JS; Vidailhet M
Ann Neurol; 2011 Jan; 69(1):111-8. PubMed ID: 21280081
[TBL] [Abstract][Full Text] [Related]
52. [Homocysteine and its role in pathogenesis of Parkinson's disease and other neurodegenerative disorders].
Szadejko K; Szabat K; Ludwichowska A; Sławek J
Przegl Lek; 2013; 70(7):443-7. PubMed ID: 24167945
[TBL] [Abstract][Full Text] [Related]
53. Entacapone in the treatment of Parkinson's disease.
Schrag A
Lancet Neurol; 2005 Jun; 4(6):366-70. PubMed ID: 15907741
[TBL] [Abstract][Full Text] [Related]
54. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
Najib J
Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
[TBL] [Abstract][Full Text] [Related]
55. The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats.
Nissinen E; Nissinen H; Larjonmaa H; Väänänen A; Helkamaa T; Reenilä I; Rauhala P
J Neural Transm (Vienna); 2005 Sep; 112(9):1213-21. PubMed ID: 15614425
[TBL] [Abstract][Full Text] [Related]
56. Association of B vitamins status and homocysteine levels in elderly Taiwanese.
Chen KJ; Pan WH; Yang FL; Wei IL; Shaw NS; Lin BF
Asia Pac J Clin Nutr; 2005; 14(3):250-5. PubMed ID: 16169836
[TBL] [Abstract][Full Text] [Related]
57. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group.
Rinne UK; Larsen JP; Siden A; Worm-Petersen J
Neurology; 1998 Nov; 51(5):1309-14. PubMed ID: 9818851
[TBL] [Abstract][Full Text] [Related]
58. Levodopa, vitamins, ageing and the neuropathy of Parkinson's disease.
Rajabally YA; Martey J
J Neurol; 2013 Nov; 260(11):2844-8. PubMed ID: 23989342
[TBL] [Abstract][Full Text] [Related]
59. Genetic and environmental factors for hyperhomocysteinaemia and its clinical implications in Parkinson's disease.
Białecka M; Robowski P; Honczarenko K; Roszmann A; Sławek J
Neurol Neurochir Pol; 2009; 43(3):272-85. PubMed ID: 19618311
[TBL] [Abstract][Full Text] [Related]
60. Homocysteine and C-reactive protein levels in haemodialysis patients.
Koulouridis E; Tzilianos M; Katsarou A; Costimba I; Klonou E; Panagiotaki E; Georgalidis C; Krokida A; Delaportas N; Lachanas A; Karaliotas G; Kaliolia I
Int Urol Nephrol; 2001; 33(2):207-15. PubMed ID: 12092633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]